Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Seminoma 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Osteolysis 1Multiple Myeloma 1Mesothelioma, Malignant 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1Colorectal Cancer Metastatic 1Carcinoma, Small Cell 1Carcinoma 1Breast Neoplasms 1Bone Diseases, Metabolic 1Anemia 1Amyloidosis 1

Interventions

Etoposide 6Carboplatin 5Cisplatin 4Paclitaxel 3Ifosfamide 3Filgrastim 3pegfilgrastim 2Imatinib Mesylate 2Bleomycin 2tremelimumab 1sargramostim 1ixabepilone 1durvalumab 1cabozantinib 1aldesleukin 1Thiotepa 1Therapeutics 1Sunitinib 1Specimen Handling 1Nivolumab 1Mesna 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-11 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Drug Therapy 1Docetaxel 1CTLA-4 Antigen 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Seminoma × ARQ 197 × Clear all
NCT01055067 2021-04-06

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Daiichi Sankyo

Phase 2 Terminated
27 enrolled 6 charts

Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡